- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: SHR-1210 中文名稱:卡瑞利珠單抗
Camrelizumab (anti-PD-1)是一種針對PD-1的人源IgG4抗體,抑制PD-L1和PD-L2與PD-1的結(jié)合,具有抑制免疫檢查點效果和抗腫瘤活性;MW: 146.3 KD。
客戶使用Selleck的Camrelizumab (anti-PD-1)發(fā)表文獻1篇
抑制劑名稱 | 引文數(shù)量 | PD-1/PD-L1 interaction | PD-1 | PD-L1 | PD-1/PD-L1 | 其他靶點 |
---|---|---|---|---|---|---|
GS-4224 | 0 | |||||
INCB086550 | 1 | |||||
BMS-1001 | 0 | |||||
BMS-1166 | 5 | |||||
Durvalumab (anti-PD-L1) | 16 | PD-L1/CD80 | ||||
Atezolizumab (anti-PD-L1) | 64 | |||||
Nivolumab (anti-PD-1) | 75 | PD-1/PD-L2 interaction | ||||
PD-1/PD-L1 Inhibitor 3 | 13 | |||||
BMS-1 | 12 | |||||
BMS202 | 23 | |||||
CA-170 (AUPM-170) | 0 | |||||
SR 0987 | 1 | IL17,RORγt | ||||
Spartalizumab (anti-PD-1) | 1 | |||||
Camrelizumab (anti-PD-1) | 1 | |||||
AUNP-12 | 3 | |||||
Pembrolizumab (anti-PD-1) | 63 |
產(chǎn)品描述 | Camrelizumab (anti-PD-1)是一種針對PD-1的人源IgG4抗體,抑制PD-L1和PD-L2與PD-1的結(jié)合,具有抑制免疫檢查點效果和抗腫瘤活性;MW: 146.3 KD。 | |
---|---|---|
靶點 |
|
CAS號 | 1798286-48-2 |
---|---|
配制 | PBS buffer, pH 7.2 |
推薦同型對照 | Human IgG4 |
來源 | CHO cells |
除菌 | 0.2 μM filtered |
儲存條件(自收到貨起) | Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Selleck收集了市面上此靶點抗體的常見克隆號,并調(diào)查了這些克隆在文獻中的使用情況(數(shù)據(jù)截至2024年9月)。結(jié)果顯示,Selleck選擇的克隆號更廣泛被使用。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
How to store the antibody?
回答:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.